Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
| CAPS Rating |
|
|---|---|
| Open | $6.29 |
| Previous Close | $6.40 |
| Daily Range | $6.12 - $6.44 |
| 52-Week Range | $5.23 - $10.42 |
| Market Cap | $164.14M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 100,820 |
| Average Daily Volume | 0 |
INFI
VS S&P 500 (SPY)
How do you think INFI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
INFI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
INFI News and Commentary
- This Drug Approval Is Good For the Industry – The Motley Fool
- WSJ BLOG/Health: A.M. Vitals: J&J Shakes Up Oversight of Consumer Unit – SmartMoney
- WSJ BLOG/Health: A.M. Vitals: J&J Shakes Up Oversight of McNeil Unit – SmartMoney
- 5 of Last Week's Biggest Losers – The Motley Fool
- Company News for January 30, 2012 - Corporate Summary – NASDAQ
- A Biotech Garage Sale – The Motley Fool
- Avoid This Biotech Stock – The Motley Fool
- 3 Stocks Near 52-Week Highs Worth Selling – The Motley Fool
- Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend – The Motley Fool
- What's Behind the Run-Up at Curis? – The Motley Fool
- Biogen R&D Head Seeks To Return Company To Biotech Roots – SmartMoney
- Biogen Names Williams As Head Of R&D; Post Empty Since '09 – SmartMoney
- Where We Are in the War on Cancer – The Motley Fool
- Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer – SeekingAlpha
- Synta Is Heating Up – SeekingAlpha
- CORRECTED - CORRECTED-BRIEF-Infinity Pharmaceuticals names new CEO – Reuters
- Now Is the Time – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
RSS Headlines
Fool UK
